$CATX
Perspective Therapeutics Inc Stock $catx

$catx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000143774924009696 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$325.0K	$1.434M	$1.434M
YoY Change	-84.25%	-22.07%	-86.72%
Cost Of Revenue
YoY Change
Gross Profit			$1.434M
YoY Change			-68.93%
Gross Profit Margin			100.0%
Selling, General & Admin	$5.878M	$21.06M	$21.06M
YoY Change	-24.98%	560.31%	123.49%
% of Gross Profit			1468.9%
Research & Development	$7.452M	$21.31M	$21.31M
YoY Change	93.21%	3512.03%	725.37%
% of Gross Profit			1486.12%
Depreciation & Amortization	$346.0K	$272.0K	$946.0K
YoY Change	92.22%	240.0%	281.45%
% of Gross Profit			65.97%
Operating Expenses	$13.33M	$42.38M	$42.38M
YoY Change	13.8%	1021.03%	252.92%
Operating Profit	-$13.01M		-$40.94M
YoY Change	15.84%		453.93%
Interest Expense	$1.180M	$833.0K	$84.00K
YoY Change	6455.56%	98.33%	-29.41%
% of Operating Profit
Other Income/Expense, Net	$1.180M	$2.000K	$835.0K
YoY Change	231.46%		601.68%
Pretax Income	-$11.83M	-$40.11M	-$40.11M
YoY Change	8.78%	1126.48%	451.51%
Income Tax	$0.00	-$2.651M	-$2.651M
% Of Pretax Income
Net Earnings	-$12.28M	-$46.51M	-$46.51M
YoY Change	3211.05%	1322.26%	539.55%
Net Earnings / Revenue	-3779.69%	-3243.24%	-3243.24%
Basic Earnings Per Share	-$0.02		-$0.17
Diluted Earnings Per Share	-$0.02	-$0.17	-$0.17
COMMON SHARES
Basic Shares Outstanding	586.9M	280.6M	267.6M
Diluted Shares Outstanding	495.1M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$180.6M	$9.238M	$9.238M
YoY Change	394.93%	-78.91%	-83.47%
Cash & Equivalents	$142.1M	$9.238M	$9.238M
Short-Term Investments	$38.53M	$0.00	$0.00
Other Short-Term Assets	$6.553M	$45.00K	$6.424M
YoY Change	555.3%	-92.5%	1436.84%
Inventory
Prepaid Expenses
Receivables	$999.0K	$1.165M	$1.165M
Other Receivables	$0.00	$10.00K	$10.00K
Total Short-Term Assets	$188.2M	$16.84M	$16.84M
YoY Change	367.39%	-68.36%	-71.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.30M	$5.576M	$6.323M
YoY Change	112.42%	231.12%	154.14%
Goodwill	$24.10M	$24.06M
YoY Change	-11.78%
Intangibles		$354.0K
YoY Change
Long-Term Investments		$133.0K	$133.0K
YoY Change		-11.33%	-11.33%
Other Assets	$482.0K	$487.0K	$182.0K
YoY Change	-14.99%	106.36%	-92.76%
Total Long-Term Assets	$90.09M	$81.05M	$81.05M
YoY Change	3.1%	1562.31%	1486.18%
TOTAL ASSETS
Total Short-Term Assets	$188.2M	$16.84M	$16.84M
Total Long-Term Assets	$90.09M	$81.05M	$81.05M
Total Assets	$278.3M	$97.89M	$97.89M
YoY Change	118.02%	68.51%	51.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.027M	$6.107M	$6.107M
YoY Change	54.54%	307.13%	532.19%
Accrued Expenses	$1.956M	$4.436M	$4.436M
YoY Change	-38.88%	303.27%	241.23%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$50.00K	$49.00K	$49.00K
YoY Change	-50.0%
Total Short-Term Liabilities	$14.50M	$15.66M	$15.66M
YoY Change	101.6%	485.35%	591.26%
LONG-TERM LIABILITIES
Long-Term Debt	$1.663M	$1.676M	$1.676M
YoY Change	-2.18%
Other Long-Term Liabilities	$27.64M	$780.0K	$780.0K
YoY Change	3848.14%	-2.5%	-12.95%
Total Long-Term Liabilities	$29.30M	$2.456M	$2.456M
YoY Change	1120.83%	207.0%	174.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.50M	$15.66M	$15.66M
Total Long-Term Liabilities	$29.30M	$2.456M	$2.456M
Total Liabilities	$48.40M	$22.71M	$22.71M
YoY Change	403.22%	558.51%	618.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$164.7M	-$152.4M
YoY Change	54.93%	43.9%
Common Stock	$394.6M	$227.6M
YoY Change	75.91%	41.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$229.9M	$75.18M	$75.18M
YoY Change
Total Liabilities & Shareholders Equity	$278.3M	$97.89M	$97.89M
YoY Change	118.02%	68.51%	51.91%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$12.28M	-$46.51M	-$46.51M
YoY Change	3211.05%	1322.26%	539.55%
Depreciation, Depletion And Amortization	$346.0K	$272.0K	$946.0K
YoY Change	92.22%	240.0%	281.45%
Cash From Operating Activities	$13.85M	-$9.008M	-$36.91M
YoY Change	-242.43%	108.04%	378.77%
INVESTING ACTIVITIES
Capital Expenditures	$9.072M	$89.00K	$1.072M
YoY Change	4413.43%	48.33%	303.01%
Acquisitions
YoY Change
Other Investing Activities	-$38.23M	$0.00	$25.46M
YoY Change	-250.14%	-100.0%
Cash From Investing Activities	-$47.30M	-$89.00K	$24.37M
YoY Change	-287.23%	-101.41%	-8682.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$364.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	166.3M	352.0K	$785.0K
YoY Change	-208010.0%		1301.79%
NET CHANGE
Cash From Operating Activities	13.85M	-9.008M	-$36.91M
Cash From Investing Activities	-47.30M	-89.00K	$24.37M
Cash From Financing Activities	166.3M	352.0K	$785.0K
Net Change In Cash	132.9M	-8.745M	-$11.76M
YoY Change	759.56%	-537.25%	48.09%
FREE CASH FLOW
Cash From Operating Activities	$13.85M	-$9.008M	-$36.91M
Capital Expenditures	$9.072M	$89.00K	$1.072M
Free Cash Flow	$4.776M	-$9.097M	-$37.99M
YoY Change	-148.13%	107.22%	376.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Registrant Name EntityRegistrantName	Perspective Therapeutics, Inc.
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000728387
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	281809852
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	281809852
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	142112766
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	142112766
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued1 NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1	136545075
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Open Tax Year OpenTaxYear	2020 2021 2022 2023
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-33407
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	41-1458152
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2401 Elliott Avenue, Suite 320
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Seattle
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	98121
CY2023	dei	City Area Code CityAreaCode	206
CY2023	dei	Local Phone Number LocalPhoneNumber	676-0900
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2023	dei	Trading Symbol TradingSymbol	CATX
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	186423142	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	586915977
CY2023	dei	Auditor Firm AuditorFirmId	444
CY2023	dei	Auditor Name AuditorName	Assure CPA, LLC
CY2023	dei	Auditor Location AuditorLocation	Spokane, Washington
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9238000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20993000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	22764000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1165000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1363000	usd
CY2023Q4	us-gaap	Notes Receivable Net NotesReceivableNet	0	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	6109000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1133000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	443000	usd
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	5301000	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	1543000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	16837000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	53215000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5576000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	371000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	747000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	50000000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	0	usd
CY2023Q4	us-gaap	Goodwill Goodwill	24062000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	487000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	175000	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	0	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	4148000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4848000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5569000	usd
CY2023Q4	us-gaap	Assets Assets	97891000	usd
CY2022Q4	us-gaap	Assets Assets	58091000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6107000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1541000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	46000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	322000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	233000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	480000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	571000	usd
CY2023Q4	catx	Accrued Payroll And Related Taxes Current AccruedPayrollAndRelatedTaxesCurrent	3128000	usd
CY2022Q4	catx	Accrued Payroll And Related Taxes Current AccruedPayrollAndRelatedTaxesCurrent	212000	usd
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	460000	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	285000	usd
CY2023Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	49000	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	0	usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	5072000	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	276000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15664000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3118000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	780000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1676000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	0	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	331000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4592000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	usd
CY2023Q4	us-gaap	Liabilities Liabilities	22712000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3449000	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	282000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	142000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	227337000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	160432000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152440000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-105932000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	75179000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	54642000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	97891000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	58091000	usd
CY2023	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	1434000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	0	usd
CY2022	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	0	usd
CY2023	us-gaap	Gross Profit GrossProfit	1434000	usd
	us-gaap	Gross Profit GrossProfit	0	usd
CY2022	us-gaap	Gross Profit GrossProfit	0	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21311000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	468000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	850000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21064000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-0	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-305000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-0	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	42375000	usd
	us-gaap	Operating Expenses OperatingExpenses	5621000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	6419000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-40941000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5621000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-6419000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	934000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	561000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	119000	usd
CY2023	us-gaap	Interest Expense InterestExpense	84000	usd
	us-gaap	Interest Expense InterestExpense	-0	usd
CY2022	us-gaap	Interest Expense InterestExpense	-0	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-17000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	835000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	561000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	119000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40106000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5060000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6300000	usd
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-9053000	usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-2275000	usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-972000	usd
CY2023	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-49159000	usd
	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-7335000	usd
CY2022	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-7272000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2651000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-46508000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7335000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-7272000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.14
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.04
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.04
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.03
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.01
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.01
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	267643000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	142103000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141987000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	67406000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	56000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1087000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-7272000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	61277000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	28000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	672000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7335000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	54642000	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	54553000	usd
CY2023	catx	Adjustments To Additional Paid In Capital Assumption Of Stock Options And Warrants At Fair Value AdjustmentsToAdditionalPaidInCapitalAssumptionOfStockOptionsAndWarrantsAtFairValue	7836000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	364000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	554000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3738000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-46508000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	75179000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-46508000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7335000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-7272000	usd
CY2023	catx	Noncash Expense Lease NoncashExpenseLease	75000	usd
	catx	Noncash Expense Lease NoncashExpenseLease	2000	usd
CY2022	catx	Noncash Expense Lease NoncashExpenseLease	4000	usd
CY2023	us-gaap	Depreciation Depreciation	946000	usd
	us-gaap	Depreciation Depreciation	138000	usd
CY2022	us-gaap	Depreciation Depreciation	248000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	298000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-22000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-305000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	40000	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	21000	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	41000	usd
CY2023	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	35000	usd
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	17000	usd
CY2022	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	32000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-17000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-0	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-0	usd
CY2023	catx	Accrued Interest On Short Term Investments AccruedInterestOnShortTermInvestments	-0	usd
	catx	Accrued Interest On Short Term Investments AccruedInterestOnShortTermInvestments	226000	usd
CY2022	catx	Accrued Interest On Short Term Investments AccruedInterestOnShortTermInvestments	-0	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	624000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023	catx	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate	15000	usd
	catx	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate	-0	usd
CY2022	catx	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate	-0	usd
CY2023	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-4170000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-0	usd
CY2022	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3738000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	672000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1087000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2651000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	426000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-245000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-405000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-359000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	76000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2673000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	325000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	249000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-46000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1584000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	573000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	236000	usd
CY2023	catx	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	89000	usd
	catx	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	83000	usd
CY2022	catx	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	52000	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-100000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	9000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	20000	usd
CY2023	catx	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	1274000	usd
	catx	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	-297000	usd
CY2022	catx	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	70000	usd
CY2023	catx	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	-159000	usd
	catx	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	32000	usd
CY2022	catx	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	-6000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36913000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6086000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7710000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1072000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	151000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	266000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18000	usd
CY2023	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	-0	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	150000	usd
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	-0	usd
CY2023	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	22764000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	12538000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	0	usd
CY2023	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	-0	usd
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	35076000	usd
CY2022	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	-0	usd
CY2023	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	-0	usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	6000000	usd
CY2022	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	-0	usd
CY2023	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	2699000	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		usd
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24373000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28839000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-284000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	68000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	554000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	28000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	56000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	364000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	65000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	785000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	56000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11755000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34897000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7938000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21175000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56072000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	64010000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9420000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21175000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56072000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9238000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20993000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55890000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9420000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21175000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56072000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	84000	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	catx	Noncash Or Part Noncash Acquisition Value Of Assets Acquired Including Goodwill NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredIncludingGoodwill	82628000	usd
	catx	Noncash Or Part Noncash Acquisition Value Of Assets Acquired Including Goodwill NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredIncludingGoodwill	0	usd
CY2022	catx	Noncash Or Part Noncash Acquisition Value Of Assets Acquired Including Goodwill NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredIncludingGoodwill	0	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	54618000	usd
	us-gaap	Stock Issued1 StockIssued1	-0	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	-0	usd
CY2023	catx	Noncash Or Part Noncash Acquisition Assumption Of Stock Options And Warrants NoncashOrPartNoncashAcquisitionAssumptionOfStockOptionsAndWarrants	-7836000	usd
	catx	Noncash Or Part Noncash Acquisition Assumption Of Stock Options And Warrants NoncashOrPartNoncashAcquisitionAssumptionOfStockOptionsAndWarrants	0	usd
CY2022	catx	Noncash Or Part Noncash Acquisition Assumption Of Stock Options And Warrants NoncashOrPartNoncashAcquisitionAssumptionOfStockOptionsAndWarrants	0	usd
CY2023	catx	Noncash Or Part Noncash Acquisition Notes Receivable And Accrued Interest Forgiven NoncashOrPartNoncashAcquisitionNotesReceivableAndAccruedInterestForgiven	-6171000	usd
	catx	Noncash Or Part Noncash Acquisition Notes Receivable And Accrued Interest Forgiven NoncashOrPartNoncashAcquisitionNotesReceivableAndAccruedInterestForgiven	0	usd
CY2022	catx	Noncash Or Part Noncash Acquisition Notes Receivable And Accrued Interest Forgiven NoncashOrPartNoncashAcquisitionNotesReceivableAndAccruedInterestForgiven	0	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	14003000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	557000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023	catx	Operating Lease Liability And Right Of Use Asset For New Lease OperatingLeaseLiabilityAndRightOfUseAssetForNewLease	811000	usd
	catx	Operating Lease Liability And Right Of Use Asset For New Lease OperatingLeaseLiabilityAndRightOfUseAssetForNewLease	0	usd
CY2022	catx	Operating Lease Liability And Right Of Use Asset For New Lease OperatingLeaseLiabilityAndRightOfUseAssetForNewLease	0	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">1.</em></b></p> </td><td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Organization</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Perspective Therapeutics, Inc. ("Perspective Therapeutics" or the "Company") (formerly known as Isoray, Inc. and Century Park Pictures Corporation) was incorporated in Minnesota in <em style="font: inherit;">1983.</em> On <em style="font: inherit;"> July 28, 2005, </em>Isoray Medical, Inc. ("Isoray") became a wholly owned subsidiary of Perspective Therapeutics pursuant to a merger. In <em style="font: inherit;"> December 2018, </em>upon approval of a majority of stockholders, Perspective Therapeutics was redomiciled to Delaware. Isoray was formed under Delaware law on <em style="font: inherit;"> June 15, 2004, </em>and on <em style="font: inherit;"> October 1, 2004, </em>acquired <em style="font: inherit;">two</em> affiliated predecessor companies which began operations in <em style="font: inherit;">1998.</em> Isoray, a Delaware corporation, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. Isoray is headquartered in Richland, Washington.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Isoray International, LLC ("International"), a Washington limited liability company, was formed on <em style="font: inherit;"> November 27, 2007, </em>and is a wholly owned subsidiary of Perspective Therapeutics.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">On <em style="font: inherit;"> February 3, 2023, </em>the Company completed the merger of Isoray Acquisition Corp., a Delaware corporation and wholly owned subsidiary of the Company, with Viewpoint Molecular Targeting, Inc. (“Viewpoint”) (such transaction being the “Merger”). Pursuant to the Merger, the Company issued 136,545,075 shares of common stock, representing approximately 49% of its fully diluted outstanding capital stock. Viewpoint is an alpha-particle radiopharmaceutical company in the alpha-emitter market developing oncology therapeutics and complementary imaging agents. For additional information, see Note <em style="font: inherit;">3,</em> <i>Merger with Viewpoint Molecular Targeting, Inc.</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">On <em style="font: inherit;"> February 6, 2023, </em>the Company announced that on <em style="font: inherit;"> January 31, 2023, </em>the Company's board of directors approved a change in the Company's fiscal year end from <em style="font: inherit;"> June 30 </em>to <em style="font: inherit;"> December 31, </em>effective as of <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Perspective Therapeutics Pty Ltd, an Australian registered company, was formed on <em style="font: inherit;"> April 14, 2023 </em>as a wholly owned subsidiary of the Company. It was formed to assist in certain clinical trial aspects of the alpha-emitter therapeutic agents.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">On <em style="font: inherit;"> December 7, 2023, </em>the Company announced the anticipated sale of its Cesium-<em style="font: inherit;">13</em> brachytherapy business. Accordingly, the financial information and operating results of the Cesium-<em style="font: inherit;">131</em> brachytherapy business have been presented as discontinued operations in the financial statements for all periods presented. Unless otherwise noted, discussion within these notes to the financial statements relates to continuing operations. For additional information, see Note <em style="font: inherit;">4,</em> <i>Discontinued Operations</i>.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b> </b></p>
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Reclassifications</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Certain prior period amounts have been reclassified to conform to the current period presentation as further described in Note <em style="font: inherit;">4,</em> <i>Discontinued Operations</i>.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p>
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	17000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	56893006
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13451938
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9559763
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Use of Estimates</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of consolidated financial statements in accordance with GAAP requires management of the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes of the Company including the allowance for doubtful accounts receivable; net realizable value of the enriched barium inventory; the estimated useful lives used in calculating depreciation and amortization on the Company’s fixed assets, patents, trademarks and other assets; estimated amount and fair value of the asset retirement obligation related to the Company’s production facilities; equity method investment; and inputs to the Black-Scholes calculation used in determining the expense related to share-based compensation including volatility and estimated lives of options granted. Accordingly, actual results could differ from those estimates and affect the amounts reported in the financial statements.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p>
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	6200000	usd
CY2023	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1518000	usd
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	783000	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	2013000	usd
CY2023	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-37021000	usd
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-12986000	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-26764000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	315000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	236000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	763000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	205000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	45000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	0	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	10000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1133000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	443000	usd
CY2023Q4	us-gaap	Notes Receivable Net NotesReceivableNet	0	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	6109000	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	6000000	usd
CY2022Q4	catx	Notes Receivable Interest Rate NotesReceivableInterestRate	0.15	pure
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6245000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	386000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	669000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5576000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	371000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	182000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	24100000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	24062000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023Q4	us-gaap	Goodwill Goodwill	24062000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	50000000	usd
CY2023Q4	catx	Indefinitelived Intangible Assets Accumulated Amortization IndefinitelivedIntangibleAssetsAccumulatedAmortization		usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	50000000	usd
CY2023Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	90000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	97000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	0	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	0	usd
CY2023Q4	catx	Estimated Hazardous Waste Removal Liability EstimatedHazardousWasteRemovalLiability	452000	usd
CY2022Q4	catx	Estimated Hazardous Waste Removal Liability EstimatedHazardousWasteRemovalLiability	442000	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1676000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	90000	usd
CY2023Q4	catx	Finitelived Patents And Trademarks Gross FinitelivedPatentsAndTrademarksGross	336000	usd
CY2022Q4	catx	Finitelived Patents And Trademarks Gross FinitelivedPatentsAndTrademarksGross	0	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	426000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	90000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	72000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	65000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	354000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	25000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	133000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	150000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	487000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	175000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	7000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	7000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	0	usd
CY2023Q4	catx	Finitelived Intangible Asset Expected Amortization After Year Four FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour	0	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y9M29D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	111000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	243000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	239000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	230000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	237000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1060000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	234000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	826000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	46000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	780000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	49000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	49000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	52000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	55000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1569000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	1725000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.32
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.26
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.55
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	21665273
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	4235000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	3269100
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3143000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	496000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	775000	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4514660
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.67
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M7D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	984000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3269100
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.75
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	256060
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.84
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	488675
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.79
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	125000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.45
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6914025
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.7
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y5M4D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4235000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.34
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	170325
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.81
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	100000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.86
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	72500
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.4
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10806200
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.56
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M4D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	21665273
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.41
CY2023	catx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Assumed In Period Gross SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodGross	24263424
CY2023	catx	Sharebased Compensation Arrangements By Sharebased Payment Award Options Assumed In Period Weighted Average Exercise Price SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice	0.17
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2434149
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.53
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1255138
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.46
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1913185
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.29
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	51132425
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.33
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6671000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	35529723
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.29
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y3M25D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5645000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	610000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3000	usd
CY2023Q4	catx	Maximum Amount Of Equity Securities That Could Be Registered MaximumAmountOfEquitySecuritiesThatCouldBeRegistered	200000000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	60000.00	usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	125000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30000.00	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	72500
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	550000	usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1913185
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
CY2021Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2645738
CY2021Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.7
CY2022	catx	Class Of Warrant Or Right Issued For Services ClassOfWarrantOrRightIssuedForServices	0
CY2022	catx	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued	0
CY2022	catx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	-0
CY2022	catx	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised	0
CY2022	catx	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	-0
CY2022	catx	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired	0
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2645738
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.7
	catx	Class Of Warrant Or Right Issued For Services ClassOfWarrantOrRightIssuedForServices	0
	catx	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued	0
	catx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	0
	catx	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised	0
	catx	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	0
	catx	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired	0
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2645738
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.7
CY2023	catx	Class Of Warrant Or Right Assumed During Period ClassOfWarrantOrRightAssumedDuringPeriod	3387093
CY2023	catx	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Assumed ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAssumed	0.27
CY2023	catx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	0
CY2023	catx	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised	0
CY2023	catx	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	-272250
CY2023	catx	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired	0.94
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5760581
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.44
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2651000	usd
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2651000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2651000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-9298000	usd
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1063000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1318000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1022000	usd
	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	3000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7159000	usd
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1040000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1222000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	709000	usd
	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	62000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	-0	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	304000	usd
	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	70000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	126000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	925000	usd
	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	0	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	0	usd
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-10000	usd
	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	12000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-32000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2651000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26758000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19145000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3214000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	722000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1379000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	562000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	902000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	240000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	176000	usd
CY2023Q4	catx	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	179000	usd
CY2022Q4	catx	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	-1000	usd
CY2023Q4	catx	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	6299000	usd
CY2022Q4	catx	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	-18000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-143000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	38828000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	20589000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29956000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	20605000	usd
CY2023Q4	catx	Deferred Tax Assets Liabilities Net Of Valuation Allowance DeferredTaxAssetsLiabilitiesNetOfValuationAllowance	8872000	usd
CY2022Q4	catx	Deferred Tax Assets Liabilities Net Of Valuation Allowance DeferredTaxAssetsLiabilitiesNetOfValuationAllowance	-15000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	387000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	6000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	12915000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	9000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	162000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	-0	usd
CY2023Q4	catx	Deferred Tax Liabilities Assets Gross DeferredTaxLiabilitiesAssetsGross	13464000	usd
CY2022Q4	catx	Deferred Tax Liabilities Assets Gross DeferredTaxLiabilitiesAssetsGross	-15000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4592000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	20605000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19074000	usd
CY2023	catx	Deferred Tax Assets Valuation Allowance Changes From Income Tax Provision DeferredTaxAssetsValuationAllowanceChangesFromIncomeTaxProvision	7159000	usd
	catx	Deferred Tax Assets Valuation Allowance Changes From Income Tax Provision DeferredTaxAssetsValuationAllowanceChangesFromIncomeTaxProvision	1040000	usd
CY2023	catx	Deferred Tax Assets Valuation Allowance Recorded To Goodwill DeferredTaxAssetsValuationAllowanceRecordedToGoodwill	1271000	usd
	catx	Deferred Tax Assets Valuation Allowance Recorded To Goodwill DeferredTaxAssetsValuationAllowanceRecordedToGoodwill	0	usd
CY2023	catx	Deferred Tax Assets Valuation Allowance Other Increases Decreases DeferredTaxAssetsValuationAllowanceOtherIncreasesDecreases	921000	usd
	catx	Deferred Tax Assets Valuation Allowance Other Increases Decreases DeferredTaxAssetsValuationAllowanceOtherIncreasesDecreases	491000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29956000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	20605000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	835000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	618000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40106000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8054000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	650000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	26000	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1434000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	usd
CY2023	us-gaap	Gross Profit GrossProfit	1434000	usd
CY2022	us-gaap	Gross Profit GrossProfit	0	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21311000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	881000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21064000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7486000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-0	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-305000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	42375000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	8672000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-40941000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-8672000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	934000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	618000	usd
CY2023	us-gaap	Interest Expense InterestExpense	84000	usd
CY2022	us-gaap	Interest Expense InterestExpense	-0	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2000	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-17000	usd
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-9053000	usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-2706000	usd
CY2023	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-49159000	usd
CY2022	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-10760000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2651000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-46508000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10760000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.14
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.06
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.03
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.02
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	267643000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	142067000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-46508000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10760000	usd
CY2023	catx	Noncash Expense Lease NoncashExpenseLease	75000	usd
CY2022	catx	Noncash Expense Lease NoncashExpenseLease	6000	usd
CY2023	us-gaap	Depreciation Depreciation	946000	usd
CY2022	us-gaap	Depreciation Depreciation	267000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	298000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-22000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-305000	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	40000	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	41000	usd
CY2023	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	35000	usd
CY2022	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	33000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-17000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-0	usd
CY2023	catx	Accrued Interest On Short Term Investments AccruedInterestOnShortTermInvestments	-0	usd
CY2022	catx	Accrued Interest On Short Term Investments AccruedInterestOnShortTermInvestments	226000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	624000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023	catx	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate	15000	usd
CY2022	catx	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate	-0	usd
CY2023	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-4170000	usd
CY2022	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3738000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	983000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2651000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	426000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-284000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-359000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1996000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	325000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	151000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1584000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	692000	usd
CY2023	catx	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	89000	usd
CY2022	catx	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	80000	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-100000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	26000	usd
CY2023	catx	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	1274000	usd
CY2022	catx	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	-11000	usd
CY2023	catx	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	-159000	usd
CY2022	catx	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	26000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36913000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10401000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1072000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	282000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18000	usd
CY2023	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	-0	usd
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	150000	usd
CY2023	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	22764000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	12538000	usd
CY2023	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	-0	usd
CY2022	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	35076000	usd
CY2023	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	-0	usd
CY2022	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	6000000	usd
CY2023	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	2699000	usd
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24373000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28988000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	68000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	554000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	28000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	364000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	65000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	785000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11755000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-39361000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21175000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	60536000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9420000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21175000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9238000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20993000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9420000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21175000	usd

Files In Submission

Name	View Source	Status
0001437749-24-009696-index-headers.html	Edgar Link	pending
0001437749-24-009696-index.html	Edgar Link	pending
0001437749-24-009696.txt	Edgar Link	pending
0001437749-24-009696-xbrl.zip	Edgar Link	pending
a01.jpg	Edgar Link	pending
catx-20231231.xsd	Edgar Link	pending
compbetaalpha.jpg	Edgar Link	pending
ex_631394.htm	Edgar Link	pending
ex_631421.htm	Edgar Link	pending
ex_631454.htm	Edgar Link	pending
ex_631459.htm	Edgar Link	pending
ex_631462.htm	Edgar Link	pending
ex_631463.htm	Edgar Link	pending
ex_644814.htm	Edgar Link	pending
ex_644815.htm	Edgar Link	pending
catx-20231231_cal.xml	Edgar Link	unprocessable
catx-20231231_def.xml	Edgar Link	unprocessable
catx-20231231_lab.xml	Edgar Link	unprocessable
catx-20231231_pre.xml	Edgar Link	unprocessable
ex_644816.htm	Edgar Link	pending
ex_644817.htm	Edgar Link	pending
ex_644997.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
isr20231231_10k.htm	Edgar Link	pending
mabs.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pipeline.jpg	Edgar Link	pending
psv.jpg	Edgar Link	pending
psv40x.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
isr20231231_10k_htm.xml	Edgar Link	completed
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
readoutdates.jpg	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stepapproach.jpg	Edgar Link	pending
vmt01_studysafety.jpg	Edgar Link	pending
vmtanet_studysafety.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CATX
Perspective Therapeutics Inc Stock $catx

2024 Q1 Form 10-K Financial Statement

#000143774924009696 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX Perspective Therapeutics Inc Stock $catx

2024 Q1 Form 10-K Financial Statement

#000143774924009696 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX
Perspective Therapeutics Inc Stock $catx